ATF3在心血管疾病中的研究进展

Research progress of ATF3 in cardiovascular diseases

心血管疾病患病率逐年升高,占中国居民死亡原因的首位。其中,心肌缺血、心肌肥厚及心衰是导致患者死亡的主要原因。研究发现,转录激活因子3(activating transcription factor 3, ATF3)同时在动脉粥样硬化(atherosclerosis, AS)、心肌缺血再灌注损伤(myocardial ischemia reperfusion injury,MIRI)、心肌肥厚及心衰(heart failure, HF)的发生发展中均有重要调控作用。本文对ATF3在这四者中发挥的作用进行了综述,旨在为ATF3作为一个新的心血管疾病治疗靶点提供理论依据。

The prevalence of cardiovascular disease is increasing year by year, and is the leading cause of death in China. Myocardial hypertrophy and heart failure are the main causes of death of the patients. In recent years, it has been found that transcription activation factor 3(ATF3) plays an important role in the development of atherosclerosis, myocardial ischemia reperfusion injury(MIRI), cardiac hypertrophy and heart failure(HF). In this paper, the role of ATF3 in these four factors is reviewed, which provides a theoretical basis of ATF3 as a new therapeutic target for cardiovascular diseases.